Last updated on November 2019

A Phase 3, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Larazotide for Relief of Persistent Symptoms in Patients with Celiac Disease on a Gluten Free Diet

Brief description of study

To assess the efficacy and safety of larazotide 0.25 mg or larazotide 0.50 mg TID versus placebo for the relief of persistent symptoms in adult patients with celiac disease on a gluten free diet (GFD)



Clinical Study Identifier: TX229392

Find a site near you

Start Over

Northwest Clinical Research Center

1951 152nd Pl NE Suite 200 Bellevue, WA United States
  Connect »